ライフサイエンスコーパス: indolent lymphoma

1 ukemia/small lymphocytic lymphoma, and other indolent lymphomas).

2 ence of the transformation of the underlying indolent lymphoma.

3 y of obinutuzumab with rituximab in relapsed indolent lymphoma.

4 after induction and safety in patients with indolent lymphoma.

5 ability in patients with relapsed/refractory indolent lymphoma.

6 optimal treatment approach for patients with indolent lymphoma.

7 warranted in untreated and alkylator-failed indolent lymphoma.

8 examethasone (FND) in patients with relapsed indolent lymphoma.

9 d clinical course of patients with so-called indolent lymphomas.

10 mens seem feasible in relapsed or refractory indolent lymphomas.

11 sing activity as a monotherapy in refractory indolent lymphomas.

12 d the only viable treatment strategy for the indolent lymphomas.

13 ost common histological subtype of so-called indolent lymphomas.

14 py induces a high LDR rate in HCV-associated indolent lymphomas.

15 ween 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have

16 lymph nodes with follicular hyperplasia, 26 indolent lymphomas (6 marginal zone lymphomas, 7 small l

17 ollicular lymphoma (FL) is the most frequent indolent lymphoma and is characterized by the accumulati

18 ctive in patients with recurrent or relapsed indolent lymphoma and results in a high percentage of CR

19 is the more effective radiation schedule for indolent lymphoma and should be regarded as the standard

20 , lasting a median of 3 months (5 months for indolent lymphomas and 3 months for intermediate- to hig

21 g 2-CdA and mitoxantrone in the treatment of indolent lymphoma, and appear to confirm clinically the

22 oclonal antibody therapy, offers promise for indolent lymphoma, and should further improve prognosis

23 iffuse large-B-cell lymphoma, no evidence of indolent lymphoma, and were previously untreated.

24 ffuse large B-cell lymphoma (DLBCL), two had indolent lymphomas, and four had chronic lymphocytic leu

25 insights into the underlying biology of the indolent lymphomas are anticipated to help guide therapy

26 Chronic leukemias and indolent lymphomas can be well controlled for years in m

27 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV <or= 13.

28 ith diffuse large B-cell lymphoma, four with indolent lymphomas) had evidence of clinical activity, a

29 f hematopoietic stem cell transplantation in indolent lymphoma has been defined by the adoption of th

30 otoxic agents and immunotherapy for advanced indolent lymphomas have been encouraging.

31 essive lymphoma is found in a LN biopsy with indolent lymphoma in a BM biopsy.

32 sease and/or the screening and monitoring of indolent lymphoma in individual patients.

33 re lacking, and it is uncertain whether this indolent lymphoma is defined by age or may occur in adul

34 with organ transplantation in patients with indolent lymphoma is limited, and it is unknown how the

35 FL as a biologically and clinically distinct indolent lymphoma of children and adults characterized b

36 Rituximab as monotherapy for indolent lymphoma of the orbit and conjunctiva may be as

37 e survival (PFS) or overall survival (OS) of indolent lymphoma patients.

38 o many agents available for the treatment of indolent lymphomas, questions that have to be addressed

39 Treatment for patients with stage IV indolent lymphoma ranges from watchful waiting to intens

40 total of 175 patients with relapsed CD20(+) indolent lymphoma requiring therapy and with previous re

41 Although most patients with indolent lymphomas respond to initial therapy, virtually

42 Indolent lymphoma should not be considered an absolute c

43 ns between slope and risk were strongest for indolent lymphoma subtypes.

44 e in this association between aggressive and indolent lymphoma subtypes.

45 h relapsed follicular, mantle cell, or other indolent lymphomas such as marginal zone lymphoma.

46 ovides the first phase III data in untreated indolent lymphoma that MR after chemotherapy significant

47 hallenges in the management of patients with indolent lymphoma, the difficulties starting with the di

48 al to profoundly impact clinical outcomes in indolent lymphoma therapy.

49 toxantrone in patients with alkylator-failed indolent lymphoma to determine the maximum-tolerated dos

50 The treatment of transformed indolent lymphoma (TRIL) often includes salvage chemothe

51 patients with previously untreated stage IV indolent lymphoma were evaluable (73 on FND; 69 on ATT).

52 ty-one patients with recurrent or refractory indolent lymphoma were treated with a regimen of fludara

53 e not equivalent when accelerated E mu-N-myc indolent lymphomas were compared to accelerated c-myc pr

54 For example, patients with indolent lymphoma who achieved a complete remission with

55 ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%.

56 l transplantation is a promising therapy for indolent lymphoma with minimal toxicity and myelosuppres

57 In two patients MC had evolved into an indolent lymphoma with monoclonal B-cell lymphocytosis.

58 improvement in the survival of patients with indolent lymphoma, with patients continuing to have an u